Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)

Chest

Volumn 133, Issue 6 SUPPL. 6, 2008, Pages 340S-380S

  Warkentin, Theodore E ^a,e   Greinacher, Andreas ^b   Koster, Andreas ^c   Lincoff, A Michael ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

Argatroban; Bivalirudin; Coumarin induced necrosis; Danaparoid; Fondaparinux; Heparin induced thrombocytopenia; IgG; Lepirudin; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; COUMARIN; DANAPAROID; DEXTRAN 70; FONDAPARINUX; HEPARIN; HIRULOG; ILOPROST; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PROSTACYCLIN; RECOMBINANT HIRUDIN; TIROFIBAN; VITAMIN K GROUP; WARFARIN;

ADRENAL VEIN THROMBOSIS; ANAPHYLAXIS; ARTERY THROMBOSIS; BLEEDING; CARDIOPULMONARY ARREST; CARDIOPULMONARY INSUFFICIENCY; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEVER; GANGRENE; HEART INFARCTION; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INJECTION SITE THROMBOSIS; INTERNATIONAL NORMALIZED RATIO; LIMB ISCHEMIA; LUNG EMBOLISM; MAINTENANCE THERAPY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SKIN NECROSIS; STROKE; TACHYCARDIA; THORAX PAIN; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT RESPONSE; VENOUS LIMB GANGRENE;

COUMARINS; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PLATELET COUNT; THROMBOCYTOPENIA;

EID: 45949103154     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0677     Document Type: Article

References (284)

1. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335
2. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2514-2518
3. Hong AP, Cook DJ, Sigouin CS, et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101:3049-3051
4. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101:2955-2959
5. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003; 110:73-82
6. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 67-116
7. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced dirombocytopenia. 4th ed. New York, NY; Informa Healthcare USA, 2007; 21-66
8. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1998; 56:12-16
9. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:502-507
10. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106:629-635
11. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79:1-7
12. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121:535-555
13. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126:1415-1423
14. Greinacher A, Lubenow N, Hinz P, et al. Heparin-induced thrombocytopenia [in German]. Dtsch Ártz 2003; 100: A2220-A2229
15. Greinacher A, Eichler P, Lietz T, et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia [letter]. Blood 2005; 106:2921-2922
16. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 2005; 94:132-135
17. Pouplard C, May MA, Ioehmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-2536
18. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92:494-497
19. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708
20. Warkentin TE, Sheppard JI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146:341-346
21. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2:448-157
22. Warkentin TE, Sheppard JI. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006; 20: 259-272
23. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76:420-426
24. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4:759-765
25. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost 1992; 68:95-96
26. Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002; 99:1230-1236
27. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparimplatelet factor 4. Blood 1998; 91:916-922
28. Amiral J, Pouplard C, Vissac AM, et al. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 2000; 109:336-341
29. Warkentin TE, Sheppard JI, Moore JC, et al. The quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008 [Epub ahead of print]
30. Council for International Organization of Medical Sciences. Working Party IV. Geneva, Switzerland: Council for International Organization of Medical Sciences, 1998
31. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286-1292
32. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122:37-42
33. Ganzer D, Gutezeit A, Mayer G, et al. Prevention of thromboembolism as a cause of thromboembolic complications: a study of the incidence of heparin-induced thrombocytopenia type II [in German]. Z Orthop Ihre Grenzgeb 1997; 135:543-549
34. Ahmad S, Haas S, Hoppensteadt DA, et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res 2002; 108:49-55
35. Francis JL, Palmer GP III, Moroose R, et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003; 75:17-22
36. Lindhoff-Last E, Nakov R, Misselwitz F, et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated heparin or low-molecular-weight heparin. Br J Haematol 2002; 118:1137-1142
37. Pohl C, Kredteck A, Bastians B, et al. Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. Neurology 2005; 64:1285-1287
38. Prandoni P, Siragusa S, Girolami B, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005; 106:3049-3054
39. Warkentin TE, Greinacher A. Inside blood commentary. Blood 2005; 106:2931-2932
40. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710-2715
41. Warkentin TE, Sheppard JI, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108:2937-2941
42. Sanson BJ, Lensing AWA, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-672
43. Lepereq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001; 108:1134-1140
44. Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol 2000; 107:1116-1121
45. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism. Blood 2005; 106:401-407
46. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001; 185:148-152
47. Ansell JE, Clark WP Jr, Compton CC. Fatal reactions associated with intravenous heparin. Drug Intell Clin Pharm 1986; 20:74-75
48. Popov D, Zarrabi MH, Foda H, et al. Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997; 29:449-452
49. Ansell J, Slepchuk N Jr, Kumar R, et al. Heparin-induced thrombocytopenia: a prospective study. Thromb Haemost 1980; 43:61-65
50. Green D, Martin GJ, Shoichet SH, et al. Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin. Am J Med Sci 1984; 288:60-64
51. Powers PJ, Kelton JG, Carter CJ. Studies on the frequency of heparin-associated thrombocytopenia. Thromb Res 1984; 33:439-443
52. Bailey RT Jr, Ursick JA, Heim KL, et al. Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by new process, and porcine intestinal heparin. Drug Intell Clin Pharm 1986; 20:374-378
53. Cipolle RJ, Rodvoid KA, Seifert R, et al. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit 1983; 5:205-211
54. Ramirez-Lassepas M, Cipolle RJ, Rodvold KA, et al. Heparin-induced thrombocytopenia in patients with cerebrovascular ischemic disease. Neurology 1984; 34:736-740
55. Bell WR, Tomasulo PA, Alving FM, et al. Thrombocytopenia occurring during the administration of heparin: a prospective study in 52 patients. Ann Intern Med 1976; 85:155-160
56. Alving BM, Shulman NR, Bell WR, et al. In vitro studies of heparin-induced thrombocytopenia. Thromb Res 1977; 11: 827-834
57. Powers PJ, Cuthbert D, Hirsh J. Thrombocytopenia found uncommonly during heparin therapy. JAMA 1979; 241: 2396-2397
58. Gallus AS, Goodall KT, Beswick W, et al. Heparin-associated thrombocytopenia: case report and prospective study. Aust NZJ Med 1980; 10:25-31
59. Holm HA, Eika C, Laake K. Thrombocytes and treatment with heparin from porcine mucosa. Scand J Haematol 1980; 36(suppl):81-84
60. Monreal M, Lafoz E, Salvador R, et al. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalemia. Eur J Clin Pharmacol 1989; 37:415-418
61. Malcolm ID, Wigmore TA, Steinbrecher UP. Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin. Can Med Assoc J 1979; 120:1086-1088
62. Rao AK, White GC, Sherman L, et al. Low incidence of thrombocytopenia with porcine mucosal heparin: a prospective multicentre study. Arch Intern Med 1989; 149:1285-1288
63. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303:543-548
64. Louridas G. Heparin-induced thrombocytopenia. S Afr J Surg 1991; 29:50-52
65. Trossaert M, Gaillard A, Commin PL, et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass. Br J Haematol 1998; 101:653-655
66. Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128:837-841
67. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4:281-282
68. Romeril KR, Hickton CM, Hamer JW, et al. Heparin induced thrombocytopenia: case reports and a prospective study. NZ Med J 1982; 95:267-269
69. Weitberg AB, Spremulli E, Cummings FJ. Effect of low-dose heparin on the platelet count. South Med J 1982; 75:190-192
70. Johnson RA, Lazarus KH, Henry DH. Heparin-induced thrombocytopenia: a prospective study. Am J Hematol 1984; 17:349-353
71. Verma AK, Levine M, Shalansky SJ, et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23:745-753
72. Mayo DJ, Cullinane AM, Merryman PK, et al. Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices. Support Care Cancer 1999; 7:425-427
73. Kadidal VV, Mayo DJ, Horne MK. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. J Intern Med 1999; 246:325-329
74. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1333-1840
75. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873
76. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702
77. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106:3791-3796
78. Pouplard C, Couvret C, Regina S, et al. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005; 3:2813-2815
79. Greinacher A, Albau S, Dummel V, et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74:886-892
80. Elalamy I, Lecrubier C, Potevin C, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 1384-1385
81. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8:114-117
82. Kuo KHM, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology 2005; 10:271-275
83. Efird LE, Koekler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006; 40:1383-1387
84. Bradner JE, Eikelboom JW. Emerging anticoagulants and heparin-induced thrombocytopenia: indirect and direct factor Xa inhibitors and oral thrombin inhibitors. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 4th ed. New York, NY: Informa Healthcare USA, 2007; 441-461
85. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux [letter]. N Engl J Med 2007; 356:2653-2654
86. Amiral J, Peynand-Debayle E, Wolf M, et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996; 52:90-95
87. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5:1666-1673
88. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 227-260
89. Warkentin TE. Pseudo-heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 261-282
90. Kitchens CS. Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. Am J Hematol 2004; 76:69-73
91. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006; 408-414
92. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
93. Rice L, Attisha WK, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136:210-215
94. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin [letter]. N Engl J Med 2003; 348:1067-1069
95. Levine RL, Hursting MJ, Drexler A, et al. Heparin-induced thrombocytopenia in the emergency department. Ann Emerg Med 2004; 44:511-515
96. Smythe MA, Stephens JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med 2005; 45:417-419
97. Jackson MR, Neilson WJ, Lary M, et al. Delayed-onset heparin-induced thrombocytopenia and thrombosis after intraoperative heparin anticoagulation: four case reports. Vasc Endovascular Surg 2006; 40:67-70
98. Arepally GM, Ortel TL. Clinical practice: heparin-induced thrombocytopenia. N Engl J Med 2006; 355:809-817
99. Prechel MM, McDonald MK, Jeske WP, et al. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 2005; 3:2168-2175
100. Goldhaber SZ, Hirsch DR, MacDougall RC, et al. Prevention of venous thrombosis after coronary artery bypass surgery (a randonrized trial comparing two mechanical prophylaxis strategies). Am J Cardiol 1995; 76:993-996
101. Visentin GP, Malik M, Cyganiak KA, et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 1996; 128:376-383
102. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 2121-2131
103. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large tertiary care, teaching hospital. Chest 2007; 131:1644-1649
104. Lillo-Le Louet A, Bontouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004; 2:1882-1888
105. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 283-317
106. Warkentin TE. Heparin-induced thrombocytopenia: igG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/ anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996; 10:249-258
107. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127:804-812
108. Warkentin TE, Sikov WM, Lillierap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999; 62:44-48
109. Gailani D, Reese EP Jr. Anticoagulant-induced skin necrosis in a patient with hereditary deficiency of protein S. Am J Hematol 1999; 60:231-236
110. Smythe MA, Warkentin TE, Stephens JL, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002; 71:50-52
111. Gatti L, Carnelli V, Rusconi R, et al. Heparin-induced thrombocytopenia and warfarin-induced skin necrosis in a child with severe protein C deficiency: successful treatment with dermatan sulfate and protein C concentrate. J Thromb Haemost 2003; 1:387-388
112. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164:66-70
113. Warkentin TE, Whitlock RP, Teoh KHT. Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenoearcinoma-associated thrombotic endocarditis. Am J Hematol 2004; 75:56-62
114. Warkentin TE, Roberts RS, Hirsh J, et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127:1857-1861
115. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost 2006; 4:894-896
116. Schenk S, El-Banayosy A, Prohaska W, et al. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. J Thorac Cardiovasc Surg 2006; 131: 1373-1381
117. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heaprin-induced thrombocytopenia? Am J Hematol 2007; 82:1037-1043
118. Gerhart TN, Yett HS, Robertson LK, et al. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip: a prospective, randomized trial. J Bone Joint Surg Am 1991; 73:494-502
119. Leyvraz P, Bachmann F, Bohnet J, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine. Br J Surg 1992; 79:911-914
120. Eriksson BI, Wille-Jörgensen P, Kälebo P, et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337:1329-1335
121. McRae SJ, Al Muslahi M, Duncan EM, et al. Evaluation of a pre-test clinical score for the diagnosis of HIT [abstract]. J Thromb Haemost 2007; O-S-070
122. Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 345-378
123. Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 379-408
124. Bartholomew JR. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 409-439
125. Chong BH, Magnani HN. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 4th ed. New York, NY: Informa Healthcare USA, 2007; 319-343
126. Anonymous. Fondaparinux (Arixtra), a new anticoagulant. Med Lett Drugs Ther 2002; 44:43-44
127. Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost 2001; 86:1170-1175
128. Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85:950-957
129. Warkentin TE. Danaparoid (Orgaran®) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG [abstract]. Blood 1996; 88(suppl 1):626a
130. Lubenow N, Warkentin TE, Greinacher A, et al. Results of a systematic investigation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006; 117:507-515
131. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70:554-561
132. Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997; 8:74-81
133. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT): a report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95:967-981
134. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia: alternative anticoagulation in pregnancy and lactation. Semin Thromb Haemost 2002; 28:439-446
135. Lindhoff-Last E, Magnani HN, Kreutzenbeck H-J. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93:63-69
136. Schindewolf M, Magnani HN, Lindhoff-Last E. Danaparoid in pregnancy in cases of heparin intolerance: use in 59 cases. Hamostaseologie 2007; 27:89-97
137. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73-80
138. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100:587-593
139. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96:846-851
140. Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HIT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3:2428-2436
141. Lubenow N, Eichler P, Greinacher A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia [abstract]. Blood 2002; 100(suppl 1):502a
142. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004; 104:3072-3077
143. Lewis BE, Wallis DE, Berkowitz. SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843
144. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856
145. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003; 37:970-975
146. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004; 32:976-980
147. Matthai WH Jr, Hursting MJ, Lewis BE, et al. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 2005; 116:121-126
148. Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 2005; 19:183-188
149. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Haemost 2005; 11:279-287
150. Begelman SM, Hursting MJ, Aghababian RV, et al. Heparin-induced thrombocytopenia from venous thromboembolism treatment. J Intern Med 2005; 258:563-572
151. Reddy BV, Grossman EJ, Trevino SA, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005; 39:1601-1605
152. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129:1167-1175
153. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129:1407-1416
154. Arnold RJ, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. Cardiol Rev 2006; 14:7-13
155. Murray PT, Hursting MJ. Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Ren Fail 2006; 28:537-539
156. Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006; 22:169-176
157. Gray A, Wallis DE, Hursting MJ, et al. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clin Appl Thromb Haemost 2007; 13:353-361
158. Jang IK, Hursting MJ, McCollum D. Argatroban therapy in patients with coronary artery disease and heparin-induced thrombocytopenia. Cardiology 2007; 109:172-176
159. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96:2373-2378
160. Greinacher A, Eichler P, Albrecht D, et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003; 101: 2617-2619
161. Eichler P, Lubenow N, Strobel U, et al. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 2004; 103:613-616
162. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108:2062-2065
163. Cardenas GA, Deitcher SR. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin Proc 2005; 80:491-493
164. Badger NO, Butler K, Hallman LC. Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia. Pharmacotherapy 2004; 24:1800-1803
165. Fatal anaphylactic shock caused by lepirudin. Prescrire Int 2003; 12:64
166. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 1995; 11:511-514
167. Francis JL, Drexler A, Gwyn G, et al. Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia [abstract]. Blood 2003; 102(suppl 1):164a
168. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with heparin and/or renal dysfunction. Pharmacotherapy 2006; 26:452-460
169. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006; 26:461-468
170. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006; 108:1492-1496
171. Hacquard M, De Maistre E, Lecompte T. Lepirudin: is the approved dosing schedule too high? J Thromb Haemost 2005; 3:2593-2596
172. De Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 2003; 37:1237-1240
173. Reichert MG, MacGregor DA, Kincaid EH, et al. Excessive argatroban anticoagulation for heparin-indueed thrombocytopenia. Ann Pharmacother 2003; 37:652-654
174. Baghdasarian S, Singh I, Militello M, et al. Argatroban dosage in critically ill patients with HIT [abstract]. Blood 2004; 104:493a
175. Koster A, Buz S, Hetzer R, et al. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARGE03 trial. J Thorac Cardiovasc Surg 2006; 132:699-700
176. Koster A, Hentschel T, Groman T, et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 2007; 133:1376-1377
177. Beiderlinden M, Treschan TA, Gorlinger K, et al. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007; 41:749-754
178. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004; 38:25-29
179. Kodityal S, Nguyen PH, Kodityal A, et al. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006; 21:86-92
180. Smythe M, Stephens JL, Koerber JM, et al. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Haemost 2005; 11:371-374
181. Kiser TH, Jung R, MacLaren R, et al. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005; 25:1736-1745
182. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007; 24:489-499
183. Rice L, Hursting MJ, Baillie GM, et al. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007; 47:1028 -1034
184. Kodityal S, Manhas AH, Udden M, et al. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur J Haematol 2003; 71:109-113
185. Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008; 29:66-74
186. Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999; 1616-1620
187. Schenk JF, Pindur G, Stephan B, et al. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Haemost 2003; 9:25-32
188. Warkentin TE. Heparin-induced thrombocytopenia, part 2: clinical course and treatment. J Crit Illn 2002; 17:215-221
189. Tardy B, Tardy-Poncet B, Fournel P, et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia [letter]. Thromb Haemost 1999; 82:1199-1200
190. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2:2133-2137
191. Sobel M, Adelman B, Szentpetery S, et al. Surgical management of heparin-associated thrombocytopenia: strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg 1988; 8:395-401
192. Jouanny P, Jeandel C, Laurain MC, et al. Heparin-induced thrombocytopenia and vena cava filter: difficulties of treatment. J Mal Vasc 1993; 18:320-322
193. Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 2001; 135:589-593
194. Wallis DE, Quintos R, Wehrmacher W, et al. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 1999; 116:1333-1338
195. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998; 35(suppl 5):17-25
196. Thomas D, Block AJ. Thrombocytopenia, cutaneous necrosis, and gangrene of the upper and lower extremities in a 35-year-old man. Chest 1992; 102:1578-1580
197. Gupta AK, Kovaes MJ, Sander DN. Heparin-induced thrombocytopenia. Ann Pharmacother 1998; 32:55-59
198. Battey PM, Salam AA. Venous gangrene associated with heparin-induced thrombocytopenia. Surgery 1985; 97:618-620
199. Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85: 435-440
200. Hiatt BK, Macfarlane DE, Hursting MJ. Transition from argatroban to warfarin in patients with heparin-induced thrombocytopenia [abstract]. Blood 2001; 98:91b
201. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17: 105-125
202. Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94:958-964
203. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: antibody is not heparin-specific. Thromb Haemost 1992; 67:545-549
204. Ranze O, Eichner A, Lubenow N, et al. The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): a cohort study [abstract]. Ann Hematol 2000; 79(suppl 1):P198
205. Contreras M. The appropriate use of platelets: an update from the Edinburgh Consensus Conference. Br J Haematol 1998; 101(suppl 1):10-12
206. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122:10-23
207. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. N Engl J Med 1976; 295:237-241
208. Cimo PL, Moake JL, Weinger RS, et al. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol 1979; 6:125-133
209. Rosovsky RP, Abdel-Wahad OI, Van Cott EM, et al. The incidence of thrombosis in patients with isolated heparin induced thrombocytopenia [abstract]. Blood 2006; 108:312a
210. Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]. N Engl J Med 2000; 343:515
211. Nuttall GA, Oliver WC, Santrach PJ, et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 2003; 96:344-350
212. Olinger GN, Hussey CV, Olive JA, et al. Cardiopulmonary bvpass for patients with previously documented heparin-indued platelet aggregation. J Thorac Cardiovasc Surg 1984; 87:673-677
213. Selleng S, Lubenow N, Wollert HG, et al. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg 2001; 71:1041-1042
214. Lubenow N, Selleng S, Wollert HG, et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003; 75:577-579
215. Schreiber C, Dietrich W, Braun S, et al. Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies. Clin Res Cardiol 2006; 95:379-382
216. Nielsen VG, Steenwyk BL, Gurley WQ, et al. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 25:653-663
217. Poetzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 3rd ed. New York, NY: Marcel Dekker, 2004; 531-551
218. Koster A, Poetzsch B, Madlener K. Management of intraoperative anticoagulation in patients with heparin-induced thrombocytopenia undergoing cardiovascular surgery. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 4th ed. New York, NY: Informa Healthcare USA, 2007; 487-502
219. Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005; 6:1349-1371
220. Koster A, Spiess B, Chew DP, et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004; 93:356-359
221. Koster A, Yeter R, Buz S, et al. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study. J Thorac Cardiovasc Surg 2005; 129:1391-1394
222. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:925-931
223. Smedira NG, Dyke CM, Koster A, et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131:686-692
224. Koster A, Spiess B, Jurmann M, et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. Anesth Analg 2006; 103:540-544
225. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131:533-539
226. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and heparin antibodies: the CHOOSE-ON trial. Ann Thorac Surg 2007; 83:572-577
227. Dyke CM, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor 4/heparin antibodies. Ann Thorac Surg 2007; 84:836-839
228. Spiess BD, DeAnda A, McCarthy HL, et al. Off pump CABG in a patient with HITT anticoagulated with bivalirudin: a case report [abstract]. Anesth Analg 2002; 93:SCA1-SCA112
229. Bott JN, Reddy K, Krick S. Bivalirudin in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg 2003; 76:273-275
230. Vasquez JC, Vichiendilokkul A, Mahmood S, et al. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 2002; 74:2177-2179
231. Davis Z, Anderson R, Short D, et al. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 2003; 75:264-265
232. Riess FC, Pötzsch B, Bleese N, et al. Recombinant hirudin for anticoagulation during cardiopulmonary bypass in heart surgery: a clinical experience [in German]. Z Herz Thorax Gefäßchir 1997; 11:79-87
233. Koster A, Kuppe H, Hetzer R, et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998; 89:777-780
234. Koster A, Hansen R, Kuppe H, et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 2000; 14:243-248
235. Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001; 93:28-32
236. Mertzlufft F, Kuppe H, Koster A. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function. J Cardiothorac Vasc Anesth 2000; 14:304-308
237. Aouifi A, Blanc P, Piriou V, et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 2001; 71:678-683
238. Antoniou T, Kapetanakis EI, Theodoraki K, et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum 2002; 5:354-357
239. Koster A, Loebe M, Mertzlufft F, et al. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg 2000; 70:2160-2161
240. Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94:245-251
241. Koster A, Meyer O, Fischer T, et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 2001; 122:1254-1255
242. Koster A, Chew D, Merkle F, et al. Extracorporeal elimination of large concentrations of tirofiban by zero-balanced ultrafiltration during cardiopulmonary bypass: an in vitro investigation. Anesth Analg 2004; 99:989-992
243. Magnani HN, Beijering RJR, ten Cate JW, et al. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New anticoagulants for the cardiovascular patient. Philadelphia, PA: Hanley & Belfus, 1997; 487-500
244. Warkentin TE, Dunn GL, Cybulsky IJ. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia. Ann Thorac Surg 2001; 72:1730-1732
245. Carrier M, Robitaille D, Perrault LP, et al. Heparin vs danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial. J Thorac Cardiovasc Surg 2003; 125:325-329
246. Kieta DR, McCammon AT, Homan WL, et al. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 2003; 96:956-958
247. Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol 2007; 78:161-166
248. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57:177-184
249. Bivalirudin (Angiomax) for angioplasty. Med Lett Drugs Ther 2001; 43:37-38
250. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863
251. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000; 12(suppl F):14F-19F
252. Mahaffey KW, Lewis BE, Wildermann NM, et al. The Anticoagulant Therapy With Bivalirudin To Assist in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (ATBAT) Study: main results. J Invasive Cardiol 2003; 15:611-616
253. Manfredi JA, Wall RP, Sane DC, et al. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Catheter Cardiovasc Interv 2001; 52:468-472
254. Pinto DS, Sperling RT, Tu TM, et al. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2003; 58:65-68
255. Cochran K, DeMartini TJ, Lewis BE, et al. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J Invasive Cardiol 2003; 15:617-621
256. Ruppreeht HJ, Terres W, Ozbek C, et al. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol 1995; 26:1637-1642
257. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators. N Engl J Med 1995; 333:757-763
258. Hale LP, Smith K, Braden GA, et al. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Catheter Cardiovasc Diagn 1998; 45:318-322
259. Cantor WJ, Leblanc K, Garvey B, et al. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin. Catheter Cardiovasc Interv 1999; 46:352-355
260. Fischer KG. Hemodialysis in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 3rd ed. New York, NY: Marcel Dekker, 2004; 463-485
261. O'Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003; 16:61-67
262. Chuang P, Parikh C, Reilly RF. A case review: anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia. Am J Nephrol 2001; 21:226-231
263. Unver B, Sunder-Plassmann G, Horl WH, et al. Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type II. Acta Med Aust 2002; 29:146-148
264. Van der Weyden MB, Hunt H, McGrath K, et al. Delayed-onset heparin-induced thrombocytopenia: a potentially malignant syndrome. Med J Aust 1983; 2:132-135
265. Meytes D, Ayalon H, Viraq I, et al. Heparin-induced thrombocytopenia and recurrent thrombosis in pregnancy: a case report. J Reprod Med 1986; 31:993-996
266. Copplestone A, Oscier DG. Heparin-induced thrombocytopenia in pregnancy. Br J Haematol 1987; 65:248
267. Calhoun BC, Hesser JW. Heparin-associated antibody with pregnancy: discussion of two cases. Am J Obstet Gynecol 1987; 156:964-966
268. Myers B, Westby J, Strong J. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul Fibrinolysis 2003; 14:485-487
269. Gill J, Kovacs MJ. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol 1997; 90:648-650
270. Weilbach C, Rahe-Meyer N, Raymondos K, et al. Delivery of a healthy child 30 weeks after resuscitation for thromboembolism and treatment with danaparoid: 5-year follow-up. J Perinat Med 2006; 34:505-506
271. Woo YL, Allard S, Cohen H, et al. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia. Br J Obstet Gynaecol 2002; 109:466-468
272. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87:831-835
273. Mazzolai L, Hohlfeld P, Spertini F, et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108:1569-1570
274. Harenberg J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb Res 2007; 119:385-588
275. Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 2001; 67:268-269
276. Furlan A, Vianello F, Clementi M, et al. Heparin-induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin; a case report. Haematologica 2006; 91(suppl 8):ECR40
277. Huhle G, Hoffmann U, Hoffmann I, et al. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Thromb Res 2000; 99:325-334
278. Mehta R, Golichowski A. Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy. J Thromb Haemost 2004; 2:1665-1666
279. Markwardt F, Fink G, Kaiser B, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988; 43:202-207
280. Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs 2000; 14:109-125
281. Jagadeesvvaran P, Liu YC, Eddy CA. Effects of hirudin (thrombin specific inhibitor) in zebrafish embryos: a developmental role for thrombin. Blood Cells Mol Dis 1997; 23:410-414
282. Lubenow N, Hinz P, Lietz T, et al. Clinical HIT and HIT-antibody seroconversion in trauma patients receiving unfractionated heparin vs. certoparin: a randomised, double-blind study [abstract]. Transfus Med Hemother 2006; 33(suppl 1):7
283. Morris TA, Castrejon S, Devendra G, et al. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin: a metaanalysis. Chest 2007; 132: 1131-1139
284. Creekmore FM, Oderda GM, Pendleton RC, et al. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26:1438-1445